Skip to main content
Fig. 5 | Cell Regeneration

Fig. 5

From: Therapeutic application of chick early amniotic fluid: effective rescue of acute myocardial ischemic injury by intravenous administration

Fig. 5

ceAF promotes cardiomyocyte proliferation by inhibiting Hippo-YAP signaling in AC16 cells. The human cardiomyocyte cell line AC16 was used for initial in vitro studies. a Volcano plot of the RNA-seq data of ceAF treated versus the control (DMEM) treated AC16 cells (n = 3 per group). b Principal Component Analyses (PCA) of the total RNA-seq data (n = 3 per group). c Expression of genes involved in the Hippo pathway after 24 h treatment in AC16 strain. d Western blots of YAP, p-YAP S397, p-YAP S127, LATS2, and p-LATS2 in AC16 cells treated with DMEM or ceAF (n = 3 per group). e-g Quantitative analyses of the immunoblots in (d). h, i Western blots (h) and quantitative analyses (i) of intranuclear and cytoplasmic YAP, respectively, in AC16 cells treated with DMEM or ceAF (n = 3 per group). j, k Representative images and quantitative analyses of immunostaining of anti-YAP (green) and DAPI in AC16 cells treated with DMEM or ceAF (n = 6 each). Scale bar, 100 μm. l Percent of Ki67 positive cells over time after ceAF treatment in AC 16 cells with or without siRNA silencing of YAP expression. (n = 3 each). *, p < 0.05, **, p < 0.01

Back to article page